Eterna Therapeutics (NASDAQ:ERNA) Stock Price Down 4.1%

Shares of Eterna Therapeutics Inc. (NASDAQ:ERNA) fell 4.1% on Tuesday . The stock traded as low as $1.18 and last traded at $1.18. 15,237 shares changed hands during mid-day trading, a decline of 11% from the average session volume of 17,035 shares. The stock had previously closed at $1.23.

Eterna Therapeutics Price Performance

The company has a market capitalization of $6.38 million, a PE ratio of -0.21 and a beta of 4.37. The company has a 50 day moving average of $1.96 and a two-hundred day moving average of $2.34.

Eterna Therapeutics (NASDAQ:ERNA) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.85) earnings per share for the quarter.

Institutional Investors Weigh In On Eterna Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. purchased a new stake in shares of Eterna Therapeutics in the second quarter worth $26,000. Geode Capital Management LLC purchased a new stake in shares of Eterna Therapeutics in the fourth quarter worth $45,000. Sippican Capital Advisors grew its stake in shares of Eterna Therapeutics by 60.0% in the second quarter. Sippican Capital Advisors now owns 21,601 shares of the company’s stock worth $49,000 after acquiring an additional 8,101 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Eterna Therapeutics in the fourth quarter worth $56,000. Finally, CI Private Wealth LLC purchased a new stake in shares of Eterna Therapeutics in the fourth quarter worth $197,000. 6.04% of the stock is owned by hedge funds and other institutional investors.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.